Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on June 7, 2016. The filing details the results of the Company's Annual Meeting of Stockholders held on that date at the offices of Cooley LLP in Boston, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Election of Directors: All three nominees for Class I directors were elected to serve until the 2019 Annual Meeting.
- Mr. Marc Kozin: 11,893,261 votes For; 1,393,133 votes Withheld; 847,995 Broker Non-Votes.
- Dr. Roderick MacKinnon: 12,442,987 votes For; 843,407 votes Withheld; 847,995 Broker Non-Votes.
- Ms. Michelle Stacy: 12,492,626 votes For; 793,768 votes Withheld; 847,995 Broker Non-Votes.
- Ratification of Auditors: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2016.
- Votes For: 14,082,475
- Votes Against: 51,874
- Abstentions: 40
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirm the registrant name is Flex Pharma, Inc., as the input metadata referenced Decoy Therapeutics Inc.
- Verify the specific terms of the director elections and the tenure of the newly elected Class I directors.
- Review the definitive proxy statement on Schedule 14A (filed April 28, 2016) for detailed background on the proposals.
- Note that the ratification of Ernst & Young LLP covers the fiscal year ending December 31, 2016.